DSM Announces Biologics Development & Manufacturing Agreement
DSM Pharmaceutical Products recently announced it has signed a biologics contract manufacturing agreement with Paranta Biosciences Ltd of Melbourne, Australia. The contract covers the process development and cGMP manufacture by DSM of Paranta’s lead recombinant human protein. This project represents an agreement for DSM with an Australian customer at their Brisbane facility.
“Working with Paranta is an important milestone for DSM to support the local client base directly from our facility in Australia, expanding our presence in global regions,” said Alexander Wessels, CEO of DSM Pharmaceutical Products. “Our collaboration with Biopharmaceuticals Australia (BPA), the Queensland Government, and the Australian Commonwealth Government is already bringing benefits to Australia by providing biopharmaceutical firms local support and manufacturing expertise.”
Ross Barrow, CEO of Paranta Biosciences, added, “Follistatin has been shown to have great potential in treating a wide range of inflammatory and fibrotic respiratory diseases, which affect over 300 million people worldwide. Our selection of DSM as Paranta’s biologics manufacturing partner is the culmination of an extensive global search process spanning more than 9 months. We are looking forward to working with the Groningen and Brisbane groups of DSM Biologics as we continue the development and manufacturing scale-up of what we believe will be a truly exciting biotherapeutic.”
In addition to an R&D and manufacturing site in Groningen, The Netherlands, DSM is building operations in Brisbane, Australia, with the support of the governments of Queensland and the Commonwealth. The Brisbane facility is DSM’s blueprint for its “biologics plant of the future” for the production of biopharmaceuticals.
“For Biopharmaceuticals Australia, DSM’s signing-up Paranta for the new facility represents a key endorsement of the wisdom of the public sector investment in the project.” said CEO, David Hughes. “The Paranta contract is an important step in ensuring that more of the drug development value chain is retained locally. BPA, an industry-development company owned by the Queensland State Government, put together the partnering deal with DSM, and is currently project managing the final stages of the construction of the new state-of-the-art facility in cooperation with DSM Biologics.”
Paranta Biosciences is an early stage drug development company committed to the research, development, and commercialization of recombinant human follistatin for the treatment of respiratory diseases and conditions. For more information, visit www.parantabio.com.
Total Page Views: 966
